Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dr Reddy’s Posts Surprise Q3 Loss But Strong Operating Results Boost Shares

Main Markets Strong But Compliance Issues Linger

Executive Summary

Dr Reddy’s Laboratories reported an unexpected third-quarter consolidated net loss after taking a $156m charge for its generic NuvaRing contraceptive but the company’s shares jumped on a robust underlying performance that analysts praised as a "great set of numbers."

You may also be interested in...



Dr Reddy’s Snaps Up Wockhardt’s Branded Generics Business

Financially stretched Wockhardt sells select branded generic business to Dr Reddy’s for $260m, bringing the curtains down on a much anticipated transaction.

It’s A Deal, Finally: Dr Reddy’s Snaps Up Wockhardt’s Branded Gx Business

Financially stretched Wockhardt sells select branded generic business to Dr Reddy’s for $260m, bringing the curtains down on a much anticipated transaction.

Amneal Wins Race For US NuvaRing Rival

Amneal has become the first company to secure US approval for, and to launch, a generic alternative to Merck & Co’s top-selling, off-patent NuvaRing contraceptive device in the US. Other generics developers appear to be several months behind.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC141554

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel